Nuvation Bio’s Q3 2025: Clinical Progress and Financial Highlights

Nuvation Bio Inc ( (NUVB) ) has released its Q3 earnings. Here is a breakdown of the information Nuvation Bio Inc presented to its investors.

Nuvation Bio Inc. is a global oncology company dedicated to addressing challenging cancer treatments, with a focus on innovative therapies like taletrectinib (IBTROZI) and safusidenib. The company operates in the biotechnology sector, aiming to develop impactful cancer therapies.

In its third-quarter 2025 financial report, Nuvation Bio highlighted significant progress in its clinical programs and financial performance. The company successfully initiated 204 patients on IBTROZI, a treatment for advanced ROS1-positive non-small cell lung cancer (NSCLC), and reported a strong cash position of $549 million.

Key financial metrics revealed a net product revenue of $7.7 million from IBTROZI sales in the U.S., alongside a notable increase in collaboration and license agreements revenue to $5.4 million. The company also reported a net loss of $55.8 million, attributed to increased research and development expenses and selling, general, and administrative costs.

Strategically, Nuvation Bio made strides in its clinical pipeline, enrolling the first patient in a global study for safusidenib and advancing the TRUST-IV phase 3 study for IBTROZI. The company also anticipates a $25 million milestone payment from its partner Nippon Kayaku upon establishing a reimbursement price in Japan.

Looking ahead, Nuvation Bio remains focused on expanding its clinical programs and enhancing its product offerings. The management is optimistic about the potential of its therapies to address unmet medical needs in oncology, with plans to further develop and commercialize its innovative treatments.